C2i Genomics deploys an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminate the need to develop a patient-specific assay, and allowing earlier detection of recurrent cancer, to inform better treatment decisions and improve outcomes.